1 December 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Grant of Options and PDMR/director shareholdings
Proteome Sciences announces that further to the announcement of Abdelghani Omari's appointment as Chief Financial Officer on 18 August 2022 (the "Appointment Announcement"), Mr Omari has today been granted 4,000,000 options by the Company under the Company's share option scheme ("Options"). The Options are to be issued at nominal value and will vest in three equal annual tranches on 1 September 2023, 1 September 2024 and 1 September 2025. Each Option is exercisable into one Ordinary Share and once vested, can be exercised up until the 10th anniversary.
The Company notes that in the earlier Appointment Announcement, it said the Options are exercisable at the closing price of the Company's ordinary shares ("Ordinary Shares") on the date the Options are granted. The Company acknowledges that this statement was incorrect.
The Options granted to Mr Omari represent approximately 1.36 per cent of the Company's current issued share capital. In total 24,471,000 Options are now outstanding, representing approximately 8.30 per cent of the Company's current issued share capital.
Further details and the information required in accordance with the requirements of Article 19(3) of the Market Abuse Regulation No 596/2014 (as retained and applicable in the UK pursuant to section 3 of the European Union (Withdrawal) Act 2018) ("UK MAR") are set out at the end of this announcement.
For further information:
| Proteome Sciences plc | |
| Proteome Sciences plc | |
| Dr Mariola Soehngen, Chief Executive Officer | Tel: +44 (0)20 7043 2116 |
| Dr Ian Pike, Chief Scientific Officer | |
| Richard Dennis, Chief Commercial Officer | |
| Allenby Capital Limited (AIM Nominated Adviser & Broker) | |
| John Depasquale / Jeremy Porter (Corporate Finance) Tony Quirke (Sales) | Tel: +44 (0) 20 3328 5656 |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
The below notification is made in accordance with the requirements of UK MAR.
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name: | Abdelghani Omari | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status: | Chief Financial Officer | ||||
| b) | Initial notification/Amendment: | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name: | Proteome Sciences Plc | ||||
| b) | LEI: | 213800Q62ICXANKU2986 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 1p nominal value GB0003104196 | ||||
| b) | Nature of the transaction: | Grant of options under the Proteome Sciences plc 2021 Long Term Share Incentive Plan to acquire ordinary shares of 1p each in Proteome Sciences plc | ||||
| c) | Price(s) and volume(s): |
| ||||
| d) | Aggregated information: · Aggregated volume: · Price: | Single transaction as in c) above
| ||||
| e) | Date of the transaction: | 1 December 2022 | ||||
| f) | Place of the transaction: | N/A | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.